Dr. Dutra works on issues involving antitrust, competition, and merger cases in various countries and industries.
Washington, DC
Jéssica Dutra works with antitrust and competition over a wide range of industries, including healthcare, natural gas, copyright, and music. She specializes in the application of economic principles and state of the art quantitative methods in the context of litigation and damage calculation.
Dr. Dutra has taught advanced undergraduate courses in the economics of antitrust, industrial organization, and microeconomics at the University of Kansas. She is continuously engaged in both the academic and practitioner environments, serving on the American Bar Association, delivering presentations at economics conferences, publishing and peer reviewing papers on academic journals.
She is fluent in Portuguese and English, and advanced French and Spanish.
Difference-in-Differences Renaissance and Implications for Antitrust Economic Analyses
The American Bar Association Antitrust Law Section has published the article “Difference-in-Differences Renaissance and Implications for Antitrust Economic Analyses” by Director Jéssica Dutra.
BioPharma Economic Impact on the US Economy
BioPharma has experienced significant growth in recent years. This report by Robert Stoner and Jéssica Dutra, prepared for Pfizer, on the BioPharma Economic Impact in the US Economy demonstrates that the BioPharma industry in the United States provides significant value added to the GDP, a significant “multiplier” effect on employment and earnings, and a major R&D presence in the United States and worldwide.
An Overview of Market Definition in the 2023 Merger Guidelines
On December 18, 2023 the Federal Trade Commission and Department of Justice (collectively, the Agencies) released the 2023 Merger Guidelines. The new guidelines are a modification of the draft Merger Guidelines published in July 2023 and replace the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines.